Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


April 19, 2015 1:39 PM ET

Pharmaceuticals

Company Overview of Claris Lifesciences Limited

Company Overview

Claris Lifesciences Limited, together with its subsidiaries, operates as a sterile injectables pharmaceutical company worldwide. The company manufactures and markets products for anesthesia and analgesia; blood; anti-infectives, such as quinolone, beta lactum, anti-fungal, and aminoglycoside; and oncology segments. It also provides enteral nutrition products and delivery systems; and therapy, peritoneal dialysis products, and medicines for renal and transplant. In addition, the company offers injectables for various therapeutic groups, including anti-emetics, CNS, cardiology, anti-malaria, haematinics, etc in various delivery systems, such as glass bottles, vials, ampoules, and non-PVC/PVC b...

Near Parimal Railways Crossing

Ellisbridge

Ahmedabad,  380006

India

Founded in 1994

Phone:

91 79 2656 3331

Fax:

91 79 2640 8053

Key Executives for Claris Lifesciences Limited

Vice Chairman, Managing Director and Member of Shareholders/Investors Grievance Committee
Age: 34
Total Annual Compensation: $15.0M
Chief Financial Officer, Whole Time Director, Member of Audit Committee and Member of Shareholders/Investors Grievance Committee
Age: 40
Total Annual Compensation: $4.7M
Whole Time Director
Age: 61
Total Annual Compensation: $4.7M
Compensation as of Fiscal Year 2013.

Claris Lifesciences Limited Key Developments

Cadilla, Lupin, Cipla, Sun Pharma, Dr Reddy's, Pfizer and Sandoz Reportedly Eyes Takeover Of CLARIS Lifesciences's Injectables Business

Pfizer Limited (BSE:500680), Novartis AG (SWX:NOVN), Lupin Limited (BSE:500257), Cipla Limited (BSE:500087), Dr. Reddy's Laboratories Ltd. (BSE:500124), Sun Pharmaceutical Industries Limited (BSE:524715) and Cadila Healthcare Limited (BSE:532321) are reportedly looking to acquire the injectables business from Claris Lifesciences Limited (BSE:533288).

Claris Denies Sale Of Injectables Business

Claris Lifesciences Limited (BSE:533288) (Claris) denied that it has entered into negotiations for the sale of stake in the injectables business and the Board of Directors of Claris has not decided anything with respect to this.

Claris Lifesciences Limited Reports Audited Consolidated and Standalone Earnings Results for the Fourth Quarter and Year Ended December 31, 2014

Claris Lifesciences Limited reported audited consolidated and standalone earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, on consolidated basis, net sales /income from operations was INR 1,791.481 million compared to INR 1,444.259 million a year ago. Profit from operations before other income finance cost and exceptional items was INR 376.147 million compared to INR 81.435 million a year ago. Profit from ordinary activities before tax was INR 530.284 million against INR 195.813 million a year ago. Net profit was INR 902.987 million or INR 16.47 per basic and diluted share before and after extraordinary items compared to net profit of INR 185.680 million or INR 2.78 per basic and diluted share before and after extraordinary items a year ago. EBITDA was INR 734 million against INR 377 a year ago. For the year, on consolidated basis, net sales /income from operations was INR 6,253.85 million compared to INR 6,583.755 million a year ago. Profit from operations before other income finance cost and exceptional items was INR 917.977 million compared to INR 1,011.811 million a year ago. Profit from ordinary activities before tax was INR 1,265.158 million against INR 1,074.855 million a year ago. Net profit was INR 1,441.704 million or INR 23.76 per basic and diluted share before and after extraordinary items compared to net profit of INR 854.084 million or INR 13.23 per basic and diluted share before and after extraordinary items a year ago. EBITDA was INR 2,045 million against INR 2,100 a year ago. For the quarter, on standalone basis, net sales /income from operations was INR 1,580.45 million compared to INR 1,435.64 million a year ago. Profit from operations before other income finance cost and exceptional items was INR 170.241 million compared to INR 94.539 million a year ago. Profit from ordinary activities before tax was INR 332.715 million against INR 209.963 million a year ago. Net profit was INR 836.776 million or INR 15.33 per basic and diluted share before and after extraordinary items compared to net profit of INR 200.509 million or INR 3.85 per basic and diluted share before and after extraordinary items a year ago. For the year, on standalone basis, net sales /income from operations was INR 5,714.672 million compared to INR 6,287.935 million a year ago. Profit from operations before other income finance cost and exceptional items was INR 709.796 million compared to INR 969.031 million a year ago. Profit from ordinary activities before tax was INR 1,029.882 million against INR 1,032.086 million a year ago. Net profit was INR 1,348.453 million or INR 23.04 per basic and diluted share before and after extraordinary items compared to net profit of INR 812.185 million or INR 12.73 per basic and diluted share before and after extraordinary items a year ago.

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Claris Lifesciences Limited, please visit www.clarislifesciences.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.